和田哪里妇科医院治疗的好(和田上环去哪家医院治疗好) (今日更新中)

SAN FRANCISCO, June 14 (Xinhua) -- Google on Tuesday introduced several new features of its search services on desktops and smartphones, which the Internet search giant said could help users get to their search results faster.SEARCH BY VOICE, IMAGESpeaking at Google's Inside Search event in San Francisco, Mike Cohen, head of the company's speech technology efforts, said its voice search is now available in 27 languages and dialects, an estimated coverage of around 5 billion people or two-thirds of world population.Voice search has already been available in Google's mobile search application from 2008. Adding the feature to desktops is part of Google's strategy to bring mobile innovations to its desktop search.The voice search on desktop performs similarly to voice search on smartphones -- users can click the microphone button and speak the query. It is only available via Google's Chrome browser for now.Cohen noted that the volume of Google mobile speech inputs has increased by six times in the last year.Also at the event, Google introduced search-by-image, which enables users to drag-and-drop, copy-and-paste image URL, or upload the image from the desktop into the search box. They can also use a Chrome or FireFox software extension to add images to the search.Google said the search-by-image feature will be available in most countries and regions over the next few days to Chrome users, noting that it will not collect and store any images that users use.

SAN FRANCISCO, Sept. 13 (Xinhua) -- Microsoft released on Tuesday a test version of Windows 8 to developers, posing to regain ground of the tablet market dominated by Apple and Google.At its developer-focused BUILD conference held in Anaheim, California, the software giant handed out new Samsung tablet computers with a test version of the code-named "Windows 8," the first detailed preview of the system for developers and people outside Microsoft.Generally expected to be launched in fall 2012, Microsoft did not say when the system will ship or its price.Microsoft Windows President Steven Sinofsky introduces the new tablet running a test version of its touch-enabled Windows 8 at the Build conference in Anaheim, California September 13, 2011Featuring a home page filled with colorful application tiles, the new system boots up in seconds. Microsoft said the system will run on low-power ARM-based chips that power smartphones and tablets. Windows 8 also introduces a new "Metro style" interface, which run full-screen and users can multitask in two at a time."We reimagined Windows," said Steven Sinofsky, president of the Windows and Windows Live Division at Microsoft, in his keynote address to the thousands of developers in attendance. "From the chipset to the user experience, Windows 8 brings a new range of capabilities without compromise."Analysts said the new system is consumer-oriented and intuitive but it will take time to see whether it is an "iPad killer."As professionals and consumers began to spend more time on smartphones and tablets, Microsoft has not got a significant bite of the market, losing ground to Apple's iPad and devices running Google's Android system.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

NEW YORK, Aug. 19 (Xinhua) -- U.S. crude oil price edged down on Friday, ending the week with a 3.65-percent loss, the fourth straight drop in the week.With absence of major macro-economic news, crude prices on Friday mainly followed the dollar's steps. As the dollar dipped to its historic low against the Japanese yen while dropping also against the euro, oil rallied for most of the trading session.But in the last trading hour, crude turned negative because the dollar bounced back from low and the U.S. stocks turned to red. The dollar index, tracking the greenback's performance against a basket of currencies, fell 0.4 percent.Crude prices fell sharply on Thursday as fears of a double-dip recession triggered sell-off of riskier assets. WTI dropped nearly 6 percent. On Friday, the markets seemed to start calming down. But for the week, it still posted a fall of 3.65 percent.Light, sweet crude for September delivery fell moderately 12 cents, or 0.15 percent to settle at 82.26 dollars a barrel on the New York Mercantile Exchange after trading from 79.17 to 83.55 dollars.But in London, Brent crude for October delivery gained 1.63 dollars, or 1.52 percent to close at 108.62 dollars a barrel. For this week, it gained 59 cents, or 0.55 percent.

BERLIN, June 14 (Xinhua) -- A two-year-old boy became the first child to be killed by the deadly E. coli in Germany on Tuesday, officials said.To date, the terrifying EHEC infection has claimed 36 lives in Germany and one in Sweden.The child, from the northern town of Celle, died in hospital in Hanover of kidney failure and abnormal breakdown of red blood cells, two extreme symptoms of the infection with enterohaemorrhagic E. coli (EHEC), authorities in the state of Lower Saxony said.The boy became the youngest known fatal victim since the outbreak of E. coli in May. His father and 10-year-old brother were also infected with the deadly bacteria, but are recovering, doctors told a local newspaper.The Robert Koch Institute, Germany's national disease prevention and control agency, said on Tuesday that a total of 3, 235 cases had been reported in the country. Among them, 782 people are suffering from haemolytic uraemic syndrome (HUS), a life- threatening illness arising from E. coli, which would destroy human kidney and nervous system.The institute added that the number of new infections is declining sharply in recent days, with only seven reported on Tuesday.German authorities announced on Friday that bean sprouts from a farm in northern Germany were one source of the outbreak, and dropped the previous warning against eating raw cucumbers, tomatoes and lettuce. However, the food panic has caused losses worth hundreds of millions of dollars for European farmers.

来源：资阳报